Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 14/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098589 | 1.00 | LCK (0.63) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7022599 | 0.95 | LCK (0.65) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7021239 | 0.91 | LCK (0.67) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7018091 | 0.91 | LCK (0.60) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7014644 | 0.90 | LCK (0.61) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7589945 | 0.89 | LCK (0.66) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7590129 | 0.89 | LCK (0.68) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7022239 | 0.89 | LCK (0.66) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7020828 | 0.89 | LCK (0.68) | LCKJAK2JAK3NPC1LMNA | |
| SCHEMBL7588702 | 0.89 | LCK (0.61) | LCKJAK2JAK3NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |